BREAst screening Tailored for HEr (BREATHE)-A study protocol on personalised risk-based breast cancer screening programme

Jenny Liu, Peh Joo Ho, Tricia Hui Ling Tan, Yen Shing Yeoh, Ying Jia Chew, Nur Khaliesah Mohamed Riza, Alexis Jiaying Khng, Su-Ann Goh, Yi Wang, Han Boon Oh, Chi Hui Chin, Sing Cheer Kwek, Zhi Peng Zhang, Desmond Luan Seng Ong, Swee Tian Quek, Chuan Chien Tan, Hwee Lin Wee, Jingmei Li, Philip Tsau Choong Iau, Mikael Hartman, Jenny Liu, Peh Joo Ho, Tricia Hui Ling Tan, Yen Shing Yeoh, Ying Jia Chew, Nur Khaliesah Mohamed Riza, Alexis Jiaying Khng, Su-Ann Goh, Yi Wang, Han Boon Oh, Chi Hui Chin, Sing Cheer Kwek, Zhi Peng Zhang, Desmond Luan Seng Ong, Swee Tian Quek, Chuan Chien Tan, Hwee Lin Wee, Jingmei Li, Philip Tsau Choong Iau, Mikael Hartman

Abstract

Routine mammography screening is currently the standard tool for finding cancers at an early stage, when treatment is most successful. Current breast screening programmes are one-size-fits-all which all women above a certain age threshold are encouraged to participate. However, breast cancer risk varies by individual. The BREAst screening Tailored for HEr (BREATHE) study aims to assess acceptability of a comprehensive risk-based personalised breast screening in Singapore. Advancing beyond the current age-based screening paradigm, BREATHE integrates both genetic and non-genetic breast cancer risk prediction tools to personalise screening recommendations. BREATHE is a cohort study targeting to recruit ~3,500 women. The first recruitment visit will include questionnaires and a buccal cheek swab. After receiving a tailored breast cancer risk report, participants will attend an in-person risk review, followed by a final session assessing the acceptability of our risk stratification programme. Risk prediction is based on: a) Gail model (non-genetic), b) mammographic density and recall, c) BOADICEA predictions (breast cancer predisposition genes), and d) breast cancer polygenic risk score. For national implementation of personalised risk-based breast screening, exploration of the acceptability within the target populace is critical, in addition to validated predication tools. To our knowledge, this is the first study to implement a comprehensive risk-based mammography screening programme in Asia. The BREATHE study will provide essential data for policy implementation which will transform the health system to deliver a better health and healthcare outcomes.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Summary of the recruitment and…
Fig 1. Summary of the recruitment and follow-up process.
This study was approved by the National Healthcare Group Domain Specific Review. Board (reference no: 2020/01327). Written informed consent will be obtained from each participant.

References

    1. Independent UKPoBCS. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–86. doi: 10.1016/S0140-6736(12)61611-0
    1. Fischer C, Kuchenbacker K, Engel C, Zachariae S, Rhiem K, Meindl A, et al.. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet. 2013;50(6):360–7. doi: 10.1136/jmedgenet-2012-101415
    1. Yanes T, Young MA, Meiser B, James PA. Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field. Breast Cancer Res. 2020;22(1):21. doi: 10.1186/s13058-020-01260-3
    1. Gagnon J, Levesque E , Clinical Advisory Committee on Breast Cancer S, Prevention, Borduas F, Chiquette J, et al.. Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies. Curr Oncol. 2016;23(6):e615–e25. doi: 10.3747/co.23.2961
    1. Tehranifar P, Wei Y, Terry MB. Less Is More-Ways to Move Forward for Improved Breast Cancer Risk Stratification. Cancer Epidemiol Biomarkers Prev. 2021;30(4):587–9. doi: 10.1158/1055-9965.EPI-20-1627
    1. Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013(6):CD001877. doi: 10.1002/14651858.CD001877.pub5
    1. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. doi: 10.1136/bmj.g366
    1. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005. doi: 10.1056/NEJMoa1206809
    1. Canelo-Aybar C, Ferreira DS, Ballesteros M, Posso M, Montero N, Sola I, et al.. Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. J Med Screen. 2021:969141321993866.
    1. McWilliams L, Woof VG, Donnelly LS, Howell A, Evans DG, French DP. Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders’ views on a low-risk breast screening pathway. BMC Cancer. 2020;20(1):680. doi: 10.1186/s12885-020-07158-9
    1. Hall P, Easton D. Breast cancer screening: time to target women at risk. Br J Cancer. 2013;108(11):2202–4. doi: 10.1038/bjc.2013.257
    1. Raat HPJ, Lobbes MBI, Veldhuis WB. [Are The Netherlands ready for personalized breast cancer screening? Abbreviated breast MRI and contrast-enhanced mammography for screening in women with dense breasts]. Ned Tijdschr Geneeskd. 2021;165.
    1. Narod SA. Personalised medicine and population health: breast and ovarian cancer. Hum Genet. 2018;137(10):769–78. doi: 10.1007/s00439-018-1944-6
    1. Kim G, Bahl M. Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. J Breast Imaging. 2021;3(2):144–55. doi: 10.1093/jbi/wbab001
    1. Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, et al.. [Breast cancer screening: On our way to the future]. Bull Cancer. 2016;103(9):753–63. doi: 10.1016/j.bulcan.2016.06.005
    1. Teo CT, Yeo YW, Lee SC. Screening mammography behavior and barriers in Singaporean Asian women. Am J Health Behav. 2013;37(5):667–82. doi: 10.5993/AJHB.37.5.11
    1. Malhotra C, Bilger M, Liu J, Finkelstein E. Barriers to Breast and Cervical Cancer Screening in Singapore: a Mixed Methods Analysis. Asian Pac J Cancer Prev. 2016;17(8):3887–95.
    1. Wong HZ, Lim WY, Ma SS, Chua LA, Heng DM. Health Screening Behaviour among Singaporeans. Ann Acad Med Singap. 2015;44(9):326–34.
    1. Wong XY, Chong KJ, van Til JA, Wee HL. A qualitative study on Singaporean women’s views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies. BMC Cancer. 2017;17(1):776. doi: 10.1186/s12885-017-3781-8
    1. Lim SK, Teo XL, Ng JL, Li FX, Tan SM. A Survey on Singaporean Women’s Knowledge, Perception and Practices of Mammogram Screening. Ann Acad Med Singap. 2015;44(9):317–25.
    1. Loy EY, Molinar D, Chow KY, Fock C. National Breast Cancer Screening Programme, Singapore: evaluation of participation and performance indicators. J Med Screen. 2015;22(4):194–200. doi: 10.1177/0969141315589644
    1. Ho PJ, Lau HSH, Ho WK, Wong FY, Yang Q, Tan KW, et al.. Incidence of breast cancer attributable to breast density, modifiable and non-modifiable breast cancer risk factors in Singapore. Sci Rep. 2020;10(1):503. doi: 10.1038/s41598-019-57341-7
    1. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al.. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308–24. doi: 10.1007/s00268-010-0683-1
    1. Vilaprinyo E, Forne C, Carles M, Sala M, Pla R, Castells X, et al.. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014;9(2):e86858. doi: 10.1371/journal.pone.0086858
    1. Pons-Rodriguez A, Forne Izquierdo C, Vilaplana-Mayoral J, Cruz-Esteve I, Sanchez-Lopez I, Rene-Rene M, et al.. Feasibility and acceptability of personalised breast cancer screening (DECIDO study): protocol of a single-arm proof-of-concept trial. BMJ Open. 2020;10(12):e044597. doi: 10.1136/bmjopen-2020-044597
    1. Albright FS, Kohlmann W, Neumayer L, Buys SS, Matsen CB, Kaphingst KA, et al.. Population-based relative risks for specific family history constellations of breast cancer. Cancer Causes Control. 2019;30(6):581–90. doi: 10.1007/s10552-019-01171-5
    1. Wang X, Huang Y, Li L, Dai H, Song F, Chen K. Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis. Breast Cancer Res. 2018;20(1):18. doi: 10.1186/s13058-018-0947-5
    1. Nazari SS, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018;25(3):259–67. doi: 10.1007/s12282-018-0857-5
    1. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al.. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425–31. doi: 10.1136/jmg.2007.056556
    1. Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al.. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. NPJ Genom Med. 2016;1:15003. doi: 10.1038/npjgenmed.2015.3
    1. Lim GH, Borje E, Allen JC, Jr. Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic. Gland Surg. 2017;6(1):35–42. doi: 10.21037/gs.2016.11.05
    1. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343(6178):1466–70. doi: 10.1126/science.1251827
    1. Pederson HJ, Noss R. Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers. Semin Oncol. 2020;47(4):182–6. doi: 10.1053/j.seminoncol.2020.05.008
    1. Lee JY, Kim J, Kim SW, Park SK, Ahn SH, Lee MH, et al.. BRCA1/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impacts. Sci Rep. 2018;8(1):15263. doi: 10.1038/s41598-018-31859-8
    1. Mahdi KM, Nassiri MR, Nasiri K. Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev. 2013;14(6):3403–9. doi: 10.7314/apjcp.2013.14.6.3403
    1. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al.. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107(5). doi: 10.1093/jnci/djv036
    1. Chan CHT, Munusamy P, Loke SY, Koh GL, Yang AZY, Law HY, et al.. Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. Oncotarget. 2018;9(16):12796–804. doi: 10.18632/oncotarget.24374
    1. Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, et al.. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun. 2020;11(1):3833. doi: 10.1038/s41467-020-17680-w
    1. Weigel S, Heindel W, Dietz C, Meyer-Johann U, Graewingholt A, Hense HW. Stratification of Breast Cancer Risk in Terms of the Influence of Age and Mammographic density. Rofo. 2020;192(7):678–85. doi: 10.1055/a-1100-0016
    1. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91(8):1580–90. doi: 10.1038/sj.bjc.6602175
    1. Chootipongchaivat S, Wong XY, Ten Haaf K, Hartman M, Tan KB, van Ravesteyn NT, et al.. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study. Cancer Epidemiol Biomarkers Prev. 2021;30(4):653–60. doi: 10.1158/1055-9965.EPI-20-1230
    1. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, et al.. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017;109(5).
    1. Esserman LJ, Study W, Athena I. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017;3:34. doi: 10.1038/s41523-017-0035-5
    1. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al.. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541–8. doi: 10.1093/jnci/91.18.1541
    1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al.. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86. doi: 10.1093/jnci/81.24.1879
    1. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. doi: 10.1086/519795
    1. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al.. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104(1):21–34. doi: 10.1016/j.ajhg.2018.11.002
    1. Rudolph A, Song M, Brook MN, Milne RL, Mavaddat N, Michailidou K, et al.. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. Int J Epidemiol. 2018;47(2):526–36. doi: 10.1093/ije/dyx242
    1. Chikarmane SA, Cochon LR, Khorasani R, Sahu S, Giess CS. Screening Mammography Performance Metrics of 2D Digital Mammography Versus Digital Breast Tomosynthesis in Women With a Personal History of Breast Cancer. AJR Am J Roentgenol. 2021:1–8. doi: 10.2214/AJR.20.23976
    1. Evans DGR, Harkness EF, Brentnall AR, van Veen EM, Astley SM, Byers H, et al.. Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Res Treat. 2019;176(1):141–8. doi: 10.1007/s10549-019-05210-2
    1. Gail MH. Choosing Breast Cancer Risk Models: Importance of Independent Validation. J Natl Cancer Inst. 2020;112(5):433–5. doi: 10.1093/jnci/djz180
    1. Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, et al.. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. NPJ Breast Cancer. 2021;7(1):78. doi: 10.1038/s41523-021-00288-8
    1. Wong XY, Groothuis-Oudshoorn CG, Tan CS, van Til JA, Hartman M, Chong KJ, et al.. Women’s preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment. Patient Prefer Adherence. 2018;12:1837–52. doi: 10.2147/PPA.S171348
    1. Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncol. 2018;4(11):1504–10. doi: 10.1001/jamaoncol.2018.1901

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren